Home » Stocks » Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc. (SNDX)

Stock Price: $14.89 USD 0.00 (0.00%)
Updated Aug 4, 2020 4:00 PM EDT - Market open
After-hours: $14.75 -0.14 (-0.94%) Aug 4, 5:54 PM

Stock Price Chart

Key Info

Market Cap 537.45M
Revenue (ttm) 1.52M
Net Income (ttm) -56.98M
Shares Out 36.09M
EPS (ttm) -1.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $14.89
Previous Close $14.89
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 14.58 - 15.29
Day's Volume 2,020
52-Week Range 5.35 - 21.97

More Stats

Market Cap 537.45M
Enterprise Value 458.91M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 36.09M
Float 24.22M
EPS (basic) -1.88
EPS (diluted) -1.88
FCF / Share -1.45
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.82M
Short Ratio 8.03
Short % of Float 11.06%
Beta 1.83
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 354.29
PB Ratio 9.71
Revenue 1.52M
Operating Income -57.83M
Net Income -56.98M
Free Cash Flow -49.71M
Net Cash 78.54M
Net Cash / Share 2.18
Gross Margin 100.00%
Operating Margin -3,812.00%
Profit Margin -3,758.60%
FCF Margin -3,276.60%
ROA -35.34%
ROE -93.31%
ROIC -148.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 4
Overweight 1
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$23.00*
(54.47% upside)
Low
16.0
Current: $14.89
High
27.0
Target: 23.00
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue1.521.522.111.220.63-
Revenue Growth0%-28.04%72.79%94.58%--
Gross Profit1.521.522.111.220.63-
Operating Income-57.54-75.88-61.95-43.77-20.51-21.33
Net Income-56.05-73.96-60.80-47.07-104-26.36
Shares Outstanding30.4925.3721.0014.620.070.06
Earnings Per Share-1.84-2.92-2.90-3.22-1,519.27-453.02
Operating Cash Flow-50.61-68.53-47.37-35.16-2.43-14.39
Capital Expenditures--0.19-0.08-0.26-0.05-
Free Cash Flow-50.61-68.72-47.46-35.42-2.48-14.40
Cash & Equivalents59.7881.0113010586.5412.26
Total Debt0.90----13.88
Net Cash / Debt58.8881.0113010586.54-1.63
Assets63.5383.9413710989.9012.82
Liabilities31.9330.8932.8724.8723.2118.53
Book Value31.6053.0510484.14-252-153
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Syndax Pharmaceuticals, Inc.
Country United States
Employees 35
CEO Briggs W. Morrison

Stock Information

Ticker Symbol SNDX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SNDX
IPO Date March 3, 2016

Description

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates are entinostat that is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 in Phase I/II clinical trial inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; and with Tecentriq (atezolizumab) in Phase Ib/II clinical trials to treat patients with HR+ and HER2- metastatic breast cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I/II clinical trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is completed Phase Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; and Merck KGaA and Pfizer. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.